Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
1.085
-0.085 (-7.26%)
Mar 31, 2025, 3:33 PM EDT - Market open

Company Description

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.

The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.

Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.

Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment.

The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Silexion Therapeutics Corp
Silexion Therapeutics logo
Country Israel
Founded 2008
Industry Biotechnology
Sector Healthcare
CEO Ilan Hadar

Contact Details

Address:
The Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center
Jerusalem, 9112001
Israel
Phone 972 2 674 3430
Website silexion.com

Stock Details

Ticker Symbol SLXN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0002022416
ISIN Number KYG1281K1067
SIC Code 2836

Key Executives

Name Position
Ilan Hadar M.B.A. Chairman and Chief Executive Officer
Mirit Horenshtein Hadar Executive Vice President of Finance Affairs, Chief Financial Officer and Secretary
Dr. Mitchell Shirvan M.B.A., Ph.D. Chief Scientific and Development Officer

Latest SEC Filings

Date Type Title
Mar 28, 2025 8-K Current Report
Mar 27, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Mar 18, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 18, 2025 8-K Current Report
Mar 18, 2025 10-K Annual Report
Mar 14, 2025 424B3 Prospectus
Mar 14, 2025 8-K Current Report
Mar 5, 2025 8-K Current Report
Feb 12, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Feb 10, 2025 SCHEDULE 13G Filing